Profile
| Metric | Value |
|---|---|
| Full Name | Grifols, S.A. |
| Ticker | NASDAQ: GRFS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | Spain |
| IPO | |
| Indexes | Not included |
| Website | grifols.com |
| Employees | 23,833 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $9.48 | |
| Price, 1D Change | +3.16% | |
| Market Cap | $6B | |
| TTM Dividend Yield | 1.83% | |
| PE Ratio | 15.43 | |
| Beta | 0.90 | |
| Revenue | $8B | |
| Revenue, 1Y Change | +9.47% | |
| EPS | $0.25 | |
| EPS, 1Y Change | +270.18% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $0.17 | |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $0.25 | |
| EPS Estimate | $1.01 | |
| EPS Est. Change | +304.13% | |
| Revenue | $7.80B | |
| Revenue Estimate | $7.50B | |
| Revenue Est. Change | -3.82% | |
| Current Price | $9.48 | |
| Price Target | - | - |
| Price Tgt. Change | - | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $0.55 | $0.07 | -87.75% | |
| $0.83 | $0.25 | -70.07% | |
| $1.01 | N/A | +304.13% | |
| $1.20 | N/A | +379.20% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $7.15B | $7.13B | -0.39% | |
| $7.16B | $7.80B | +8.93% | |
| $7.50B | N/A | -3.82% | |
| $7.88B | N/A | +1.05% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +24.74% | |
| Price, 3Y | +5.92% | |
| Market Cap, 1Y | +24.76% | |
| Market Cap, 3Y | +6.25% | |
| Revenue, 1Y | +9.47% | |
| Revenue, 3Y | +33.80% | |
| EPS, 1Y | +270.18% | |
| EPS, 3Y | -24.12% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $9.48 | |
| SMA 200 | $8.94 | |
| SMA 200 vs Price | -5.71% | |
| SMA 50 | $8.92 | |
| SMA 50 vs Price | -5.86% | |
| Beta | 0.90 | |
| ATR | $0.24 | |
| 14-Day RSI | 63.52 | |
| 10-Day Volatility | 21.87% | |
| 1-Year Volatility | 36.64% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $0.17 | |
| Upcoming | N/A | N/A |
| Dividend Yield | 6.94% | |
| Total Dividend | $0.66 | |
| Dividends Paid | $1.04M | |
| Payout Ratio | 0.45% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $7.80B | |
| EPS | $0.25 | |
| Gross Profit | $2.84B | |
| Gross Margin | 36.46% | |
| Operating Profit | $1.22B | |
| Operating Margin | -47.95% | |
| Net Income | $230.19M | |
| Net Margin | 2.95% | |
| EBITDA | $1.69B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 1.56 | |
| Current Ratio | 2.66 | |
| Quick Ratio | 1.01 | |
| Interest Coverage | - | |
| F-Score | 6 | |
| Altman Z-Score | 1.02 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 15.43 | |
| PS Ratio | 0.78 | |
| PB Ratio | 2.80 | |
| EV/EBITDA | 8.69 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $2.31B | |
| Cash & Equivalents | $1.01B | |
| Total Assets | $22.18B | |
| Current Assets | $5.93B | |
| Total Liabilities | $13.25B | |
| Current Liabilities | $2.23B | |
| Total Debt | $9.53B | |
| Short Term Debt | $539.54M | |
| Accounts Payable | $882.56M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $7.63B | |
| Operating Expenses | $1.63B | |
| Cost Of Goods Sold | $4.96B | |
| SG&A | $0.00 | |
| D&A | $473.67M | |
| Interest Expense | $0.00 | |
| Income Tax | $250.08M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $975.87M | |
| CFI | $959.10M | |
| CFF | -$1.47B | |
| Capex | $401.70M | |
| Free Cash Flow | $574.16M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| JP Morgan | → | |
| JP Morgan | → | |
| Deutsche Bank | → | |
| JP Morgan | → | |
| Deutsche Bank | → | |
| Credit Suisse | → | |
| HSBC | → | |
| Santander | → | |
| JP Morgan | → | |
| Berenberg | → |
Analyst sentiment
Institutional ownership
Screeners with GRFS
Data Sources & References
- GRFS Official Website www.grifols.com
- GRFS Profile on Yahoo Finance finance.yahoo.com/quote/GRFS
- GRFS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/grfs
FAQ
What is the ticker symbol for Grifols, S.A.?
The ticker symbol for Grifols, S.A. is NASDAQ:GRFS
Does Grifols, S.A. pay dividends?
Yes, Grifols, S.A. pays dividends. The last payment was $0.17, with an ex-dividend date on August 12, 2025
What sector is Grifols, S.A. in?
Grifols, S.A. is in the Healthcare sector
What industry is Grifols, S.A. in?
Grifols, S.A. is in the General Drug Manufacturers industry
What country is Grifols, S.A. based in?
Grifols, S.A. is headquartered in Spain
When did Grifols, S.A. go public?
Grifols, S.A. initial public offering (IPO) was on June 2, 2011
Is Grifols, S.A. in the S&P 500?
No, Grifols, S.A. is not included in the S&P 500 index
Is Grifols, S.A. in the NASDAQ 100?
No, Grifols, S.A. is not included in the NASDAQ 100 index
Is Grifols, S.A. in the Dow Jones?
No, Grifols, S.A. is not included in the Dow Jones index
When was Grifols, S.A. last earnings report?
Grifols, S.A.'s most recent earnings report was on July 29, 2025
When does Grifols, S.A. report earnings?
The next expected earnings date for Grifols, S.A. is February 24, 2026
